University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
12-2016

Establishing a clinically relevant mouse model of human AML to
test novel transmethylation inhibitors.
Aditya Barve
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Immune System Diseases Commons, and the Neoplasms Commons

Recommended Citation
Barve, Aditya, "Establishing a clinically relevant mouse model of human AML to test novel
transmethylation inhibitors." (2016). Electronic Theses and Dissertations. Paper 2615.
https://doi.org/10.18297/etd/2615

This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional
Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator
of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who
has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

ESTABLISHING A CLINICALLY RELEVANT MOUSE MODEL OF HUMAN AML
TO TEST NOVEL TRANSMETHYLATION INHIBITORS

By
Aditya Barve
B.S. in Biology, University of Louisville, 2008

A Thesis
Submitted to the Faculty of the School of Medicine of the University of Louisville
in Partial Fulfillment of the Requirements for the Degree of

Masters of Science in Pharmacology and Toxicology

Department of Pharmacology and Toxicology
University of Louisville
Louisville, Kentucky
December 2016

i

i

ESTABLISHING A CLINICALLY RELEVANT MOUSE MODEL OF HUMAN AML
TO TEST NOVEL TRANSMETHYLATION INHIBITORS
By
Aditya Barve
B.S. in Biology, University of Louisville, 2008
A Thesis Approved on

August 18, 2016

By the following Thesis Committee

________________________________
Levi Beverly, Ph.D.
________________________________
Leah Siskind, Ph.D.
________________________________
Geoffrey Clark, Ph.D.
_____________________________
Kavitha Yaddanapudi, Ph.D.
_____________________________
Soumit Basu, M.D.
ii

ACKNOWLEDGEMENTS
I would like to acknowledge my mentor, Dr. Levi J. Beverly for his unwavering
support, patience, and guidance. His true passion for science and dauntless work
ethic have had a dramatic and lasting impact on my development as a scientist
and a person. I would also like to thank my committee, Dr. Leah Siskind, Dr.
Geoffrey Clark, Dr. Kavitha Yaddanapudi for their comments and assistance and
especially Dr. Soumit Basu for his invaluable clinical expertise.

iii

ABSTRACT
ESTABLISHING A CLINICALLY RELEVENT MOUSE OF HUMAN AML TO
TEST NOVEL TRANSMETHYLATION INHIBITORS
Aditya Barve
August 18, 2016
Acute myeloid leukemia (AML) is a highly heterogeneous clonal disorder
characterized by an accumulation of malignant immature myeloid progenitors in
the bone marrow (BM) that hinder normal hematopoiesis. Patient AML exhibits a
dramatic heterogeneity in terms of cytogenetics, disease morphology, and
associated prognoses and/or chemotherapeutic sensitivity. Thus it becomes
clearly evident that the investigation of novel therapeutics for AML will require
model systems that are capable of recapitulating this stark heterogeneity in a
patient specific manner. Furthermore, it is now understood that the surrounding
bone marrow (BM) microenvironment and supporting cells play a critical role in
leukemic progression as well as providing a chemotherapy protected sanctuary
for residual disease. Therefore, the focus of this study was the establishment and
development of a more clinically relevant mouse xenograft model of patient
derived AML that not only recapitulates patient disease but also simulates the
clinical standard of care induction therapy. The crux of our model system was the
NRGS mouse, which were not only capable of reliable high rates of engraftment
of established cell lines and patient derived AML cells, but also expresses three
human myeloid cytokines (IL-3, GM-CSF, SF). Additionally these mice were able
iv

to tolerate aggressive induction therapy at doses similar to those administered to
patients, and therapy was efficacious in prolonging the survival of mice engrafted
with patient AML. Such model systems that can simulate patient specific AML
along with the standard of care therapy, will be essential for the successful
investigation of novel, translational therapeutics.
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INTRODUCTION
Acute myeloid leukemia (AML) is a highly heterogeneous cancer
characterized by an accumulation of malignant immature myeloid progenitors in
the bone marrow (BM), peripheral blood, and rarely the central nervous system.
These malignant cells proliferate rapidly and accumulate in the BM disrupting
normal hematopoiesis. Recent studies have shown that these cells arise through
the clonal expansion of myeloid committed hematopoietic stem cells (HSC) that
have accumulated abnormal genetic alterations with age, resulting in a block in
normal hematopoietic differentiation and aberrant proliferation. Thus AML
exhibits a dramatic heterogeneity in terms of cytogenetics, disease morphology,
patient prognosis and exhibits and an even more pronounced molecular diversity.
AML is the most predominant leukemia in older patients, and the dramatic
increase in modern life expectancy is causing the incidence to skyrocket. The
incidence of new cases of AML has risen by 2.2% every year for the last 15
years. There will be an estimated 21,000 new cases of AML diagnosed this year
in the U.S. Luckily, modern chemotherapy allows approximately 60-70% of
patients to achieve CR, but unfortunately the overall 5-year survival remains poor
at only 26%, due largely to relapse.1 The extreme heterogeneity of disease
genetics and morphology presents a unique challenge for oncologists, as each
case of AML is unique with its own associated prognosis and chemotherapeutic
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sensitivity. Therefore novel, patient tailored therapies and/or treatment
paradigms that are more efficacious, specific toatient cytogenetics, and better
tolerated by elderly patients, must be developed in conjunction with standard of
care therapy.2
As mentioned previously the cytogenetic heterogeneity of AML has long
been recognized as the most important prognostic marker, as AMLs of varied
etiologies have extremely different morphology and drug sensitivity. Accordingly,
several systems of classification have been developed using differences in
genetics, cellular morphology, and immune phenotype. During the 1970s AML
was classified according to the French-American-British classification system
which relies mainly on morphology and immunological phenotype, along with
cytochemical criteria to define eight major subtypes (FAB M0 to M7).3 The
fundamental basis of this classification system was established by light
microscopy examination of malignant cells as well as some limited cytogenetics
characterizing recurrent genetic abnormalities. The numerical hierarchy of this
classification system corresponds with both the degree of maturity (lowest being
most stem) as well as the progenitor cell type from which the leukemia
developed.
While groundbreaking in its novelty and recognition of morphology and
some cytogenetics as key determining factors in overall prognosis, this system
was found to be lacking in some instances. FAB classification worked well in
instances where observed genetic lesions directly induced observed cellular
morphology and cytochemical signaling. For example in acute promyelocytic
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leukemia (APL) or acute myelomonocytic leukemia with abnormal eosinophils
(M4Eo) the morphological characteristics directly predict the genetic
abnormalities making these classifications very accurately.4 However as research
progressed it became more and more evident that morphology/cytochemistry did
not always correlate with or predict observed genetic abnormalities, and
differences in genetic abnormalities were frequently observed even in patients
with the same proposed sub-type of AML. Additionally there are many cases in
which there is absolutely no correlation between observed genetic defects and
morphology, highlighting the fact that genetic profiling of AML provides a much
more accurate system of classification and prognostic prediction. Thus, the FAB
system was the first to recognize the immense morphological heterogeneity of
AML and its value as a criteria for classification, but does not accurately convey
the genetic diversity and associated clinical outcomes of the disease.
In 2001 the World Health Organization developed an alternate system of
classification that is based on the central concept that the subgroups of AML are
actually distinct diseases through correlation of genetic, morphologic, and clinical
data. This new system of classification is significantly different from the FAB
system as it utilizes a lower blast threshold for AML diagnosis and perhaps most
significantly it defines cases of AML into unique subgroups based on biological,
clinical, and genetic characteristics. The WHO classification system was updated
in 2008 to its current format and defines seven major AML subtypes: 1.) AML
with recurrent genetic abnormalities, 2.) AML with myelodysplatic related
changes, 3.) therapy-related myeloid neoplasms, 4.) Myeloid sarcoma, 5.)
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Myeloid proliferations related to Down Syndrome, 6.) Blastic plasmacytoid
dendritic cell neoplasm, and 7.) AML otherwise not categorized (very similar to
the FAB system with some additions).4 Each major subgroup is divided into
specific subcategories based on commonly observed recurrent genetic
abnormalities, detailed karyotype analyses, and molecular abnormalities, thus
providing a much better representation of the vastly different genetic landscape
of AML even in morphologically similar cases. It becomes clearly evident that the
WHO system of classification is far superior to the FAB system in terms of scope
and descriptiveness, making it the chosen methodology for classification of AML
in modern medicine.
Current chemotherapeutic treatment of AML is broken into two distinct
phases, the first being induction therapy whose aim is to reduce the overall
leukemic blast burden and induce remission. Unfortunately, intensive induction
therapy has remained virtually unchanged since the 1970s and is effective in
inducing CR in 60-70% of patients who are able to tolerate the therapy. Sadly,
greater than 45% of patients achieving CR have a less than three year overall
survival due to relapse and refractory disease. The standard of care induction
therapy for young adults and healthy elderly patients is an intensive anthracycline
and cytarabine regimen. Also commonly referred to as “7+3”, induction therapy
utilizes a cytotoxic anthracycline like daunorubicin, idarubicin, or doxorubicin (60
or 90 mg/m2) administered the first three days along with continuous intravenous
infusion of cytarabine (Ara-C, 100mg/m2) for seven days. As previously stated
the goal of induction therapy is to induce morphological remission which is
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quantified as less than 5% blasts in the bone aspirate sample with marrow
spicules and with a count of greater than 200 nucleated cells (must lack Auer
rods and/or extramedullary disease). There must also be a platelet count greater
than or equal to 100,000 cells/ml of blood and an absolute neutrophil count that
is greater than 1000 cells/ul.5-7
Consolidation therapy, the second phase of current standard of care AML
therapy, aims to prevent relapse and reduce the minimal residual disease (MRD)
or leukemic blasts and leukemic founder cells protected from cytotoxic drug
exposure in the BM microenvironment. These cells are the causative agents of
refractory relapse, the major cause of patient mortality, and no current approved
treatment regimens exist for relapsed AML. Oncologists have two options for
consolidation therapy: 1.) Additional chemotherapy with intermediate dose
cytarabine (1.5g/m2) twice daily on days 1, 3, and 5 in 3-4 cycles or 2.) HSC
transplantation (HSCT).5 These strategies can be used at the clinician’s
discretion alone or in combination depending on the patient’s subtype of
leukemia, ability to tolerate chemotherapy, and availability of compatible donors.
Chemotherapeutic consolidation therapy (3-4 cycles) alone has been shown to
effectively improve survival and lengthen remission in patients less than 60 years
of age, leaving HSC transplant as a last resort in the result of relapse.
Comparisons of high dose (3 g/m2) and intermediate dose (1.5 g/m2) cytarabine
show equal benefit for patients under 60 years of age and therefore the
intermediate dose became the standard of care, while the high dose regimen
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showed greater efficacy in patients with CBF AML [t(8:21); or inv(16)] or AML
with mutated NPM1.8,9
In other prognostic groups allogenic stem cell transplantation remains the
most effective long term therapy for AML after, with up to 60% of patients
receiving transplant being cured. However numerous patients are deemed
ineligible for transplant due to failure to achieve CR, co-morbidities, or lack of
suitable donors. Initially age was thought to be the only determining factor in
deciding whether or not to use HSCT, but new evidence conclusively shows that
transplant success is dependent instead on active remission status and comorbidities. Also improvements in conditioning regimens, supportive care, and
haplo-identical/cord grafts have allowed a much larger segment of the patient
population to be eligible for HSCT. Still the risk of relapse remains significantly
higher in patients treated with HSCT alone and many patients are unable to
receive transplant.10,11
A special case exists for only patients who are suspected of having the
APL subtype of AML, which is treated with all trans retinoic acid even before
genetic analyses are completed and disease presence confirmed. This therapy is
clinically approved, even pre-diagnosis, and potently induces granulocytic
differentiation in malignant APL blasts inducing apoptosis, quiescence, and
increased cytotoxic drug sensitivity. Induction therapy is initiated in combination
with ATRA upon confirmation of disease, and the combination of induced
differentiation and cytotoxic chemotherapy has produced ground breaking results
in multiple clinical trials worldwide. Rates of CR were 80-90% and rates of long
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term survival conservatively exceed 75% changing APL’s former grim prognosis
into the most treatable form of AML. Considering AML is inherently different from
other cancers in that AML blasts are essentially immature cells blocked in
differentiation, novel therapies that force differentiation and maturation are highly
attractive strategies for the treatment of AML as demonstrated by the success of
ATRA in combination with induction therapy. Further study is required to develop
new drugs that are capable of inducing differentiation in multiple or hopefully all
types of AML, as demonstrated by the amazing improvement in survival and CR
rates of APL treated with ATRA.12
Chromosomal irregularities (deletions, tandem repeats, translocations
etc.) are observed in the majority of all primary AML cases (approximately 52%)
and have long been recognized as causative events that cause and promote
leukemic progression.8 Each of these chromosomal abnormalities can be
correlated with varied treatment outcomes, patient survival, and duration of
remission making cytogenetic analysis of AML a critical factor in determining
treatment options and how aggressively the leukemia is treated. For example,
AMLs that have t(8;21)(q22;q22), inv(16)(p13.1q22), or t(15;17)(q22;q12) have a
universally better prognosis with prolonged survival time as compared to other
irregularities like alterations involving chromosomes 5 and 7 (complex karyotype
AML) or 11q23 are associated with much shorter survival and diminished
chemotherapeutic sensitivity.13 Often times these genetic abnormalities result in
the expression of characteristic abnormal fusion proteins (AML-ETO, PMLRARA, MLL fusions, DEK-CAN, etc.) many of which have been directly linked to
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the observed block in differentiation and stem like phenotype of AML cells.
Interestingly, approximately 40-50% of all AML cases are actually cytogenetically
normal (CN-AML) using conventional analysis,14 showing conclusively that AML
associated genetic irregularities are not the only factor at play during the
development of myeloid leukemia. Recent work is now starting to show that the
presence or absence of specific mutations and/or altered regulation of gene
expression can be used to further differentiate various types of AML (especially
CN-AML) and possibly provide novel avenues of targeted therapy. This would
allow treatment of AML in a patient specific manner, thereby greatly improving
survival in patients harboring specific mutations or irregular patterns of gene
expression regulation resulting molecular abnormalities.
Experts are now only starting to understand the effects of dysregulated
patterns of gene expression and mutation status and how these effects mediate
leukemogenisis.4,15,16 This is of special importance in people diagnosed with CNAML which appears normal according to karyotyping analysis, and lack the
obvious genetic lesions found in other subtypes of AML. As such the prognostic
value of cytogenetic analysis is limited in these patients, but with the advent of
next-generation sequencing the genetic portrait of CN-AML has become much
clearer. It is now understood that on average CN-AMLs have 13 mutations, five
of which are recurrent “driver” mutations (directly causing leukemogenesis) and
eight are recurrent random “passenger” mutations.15 These mutations result in
molecular abnormalities in the proteins produced, and these abnormalities are
now being identified as key mediators of AML pathogenesis, as well as valuable
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prognostic markers accurately predicting clinical outcome, and as novel
druggable targets for new therapeutic approaches. Several mutations have come
to the forefront as they have extremely high relative frequency in AML, and the
most significant will be discussed here in brief.
Nucleophosmin 1 mutations (NPM1) mutations are by far the most
recurrent molecular abnormality observed in AML and can be found in
approximately 25-30% of patients.17,18 Mutations in NPM1 result in expression of
an aberrant protein that shows abnormal cellular localization in the cytoplasm
instead of the nucleus and this expression greatly promotes myeloid proliferation
and leukemogenesis.18,19 AMLs having these mutations generally present with a
monocytic morphology with a generally favorable outcome in the absence of
other mutations (namely FLT3 internal tandem deletions). This is perhaps the
most clearly evident demonstration of the importance of deep-sequencing AML to
examine potential molecular abnormalities as a way to guide therapy. AMLs with
NPM1 mutations have been conclusively shown to have a greater sensitivity to
standard of care induction chemotherapeutics and as such the overall survival is
greatly increased in both old and young patients as compared to other molecular
abnormalities.20 However NPM1 mutations are also associated with several other
recurrent abnormalities like DNA methyltransferase 3A (DNMT3A), FLT3 internal
duplications (FLT3-ITD), and isocitrate dehydrogenase mutations, most of which
in conjunction with NPM1 mutations actually worsen the prognosis.21
Fms-Like Tyrosine kinase (FLT3) was first identified in 1991 as a crucial
regulator of normal hematopoiesis and plays highly important roles in mediating
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cell survival and proliferation during hematopoiesis.22,23 Internal tandem
duplications (ITD) in region of the FLT3 gene coding for the juxta-membrane
domain or second tyrosine kinase domain of this tyrosine kinase have been
found in approximately 20% of all AML cases and 30-45% of CN-AML cases.24
These mutations create constitutively activate FLT3 promoting aberrant
proliferation in leukemic blasts.25 Thus patients with AML expressing FLT3-ITDs
exhibit extreme leukocytosis and characteristic nuclear invagination, and these
mutations are universally associated with poor prognosis, reduced survival and
marked increase in risk of relapse. As expected the occurrence of these
mutations in combination with other commonly recurring AML mutations
(including those predicting better outcome) is correlated with diminished survival
and increased rate of relapse. Interestingly, studies have also shown that nonjuxta membrane domain mutations are associated with a worse prognosis as
compared to mutations occurring in this region, again showing the clinical
significance of mutations resulting in molecular abnormalities as a predictive
biomarker for patient outcome and to guide therapy.26
Mutations of the DNMT3 gene occur in a reasonable amount of AML
cases (approximately 18-22% of all cases, 34% in CN-AML), the most common
being missense mutations affecting arginine codon 822, while less common
mutations in other codons have also been observed.21 These mutations have
now been found to actually be pre-leukemic and arise very early in the evolution
of the disease, but also persist even in times of CR. This finding is significant in
that these mutations are perhaps the most common mutations involving proteins
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that regulate gene expression in AML.27 DNMT3A is a de novo methylase that is
capable of methylation of CpG dinucleotides in the promoter regions of target
genes thereby mediating transcriptional silencing by blocking access of
transcriptional machinery to these promoters. This form of regulation, which is
independent of the genetic sequence, is known as epigenetic regulation and only
very recently have methylation and other epigenetic mechanisms become
recognized as relevant to leukemogenesis.28 Therefore it is logical that these
mutations occur very early in leukemic development, and may even play a
causative role in AML, by silencing genes required for maintenance of normal
myeloid differentiation and hematopoiesis. Finally, the value of DNMT3A
mutations as prognostic indicators remains hotly debated with some smaller
studies finding a lowered overall survival (OS) and disease free survival (DFS) in
patients expressing these mutations, while a much larger cohort study found no
correlation between DNMT3A mutation status and clinical outcome.21,29
These three mutations have the highest relative frequency of recurrence in
AML patients, but it is important to recognize that they only represent a small
fraction of the vast array of genetic and molecular abnormalities found in AML. It
becomes clearly evident that AML has a heterogeneity that is one of the most
extreme in all known cancers, and these differences result in drastically different
treatment modalities and patient prognoses. As such the development of novel
targeted therapeutics and treatment paradigms requires in vivo model systems
that are capable of faithfully recapitulating the extreme genetic and morphologic
variability found in patient AMLs. Furthermore such systems must also be able to

11

replicate standard of care induction therapy, not only as a more relevant control
(as compared to vehicle only), but also as a more clinically applicable way to test
experimental therapeutics and their translational efficacy.
Animal models have been consistently shown to better predict the success
of experimental therapeutics in clinical trials, and this holds especially true for the
investigation of new drugs for AML, as a complex and highly dynamic interaction
exists between heterogeneous populations of leukemic cells and the surrounding
BM microenvironment.30 Current evidence supports the conclusion that specific
niches within the BM microenvironment actually provide a protected sanctuary for
specific subpopulations of leukemic cells capable of self-renewal and clonogenic
proliferation, dubbed leukemic stem cells (LSCs). Seminal studies using early
xenograft models were able to establish that only the most primitive fraction (LinCD34+) of patient AML cells, and not the more mature blast population, were
capable of transferring disease to primary and secondary NOD/SCID recipient
mice.31,32 It becomes evident that a hierarchy similar to normal hematopoiesis
exists in AML, with a small population of self-renewing LSCs giving rise to a large
population of mature, clonally expanded blasts. LSCs are able to evade normal
induction chemotherapy, due to a low rate of proliferation and protection
conferred by the BM microenvironment, and are therefore thought to be the
cause of the high rate of relapse and mortality associated with AML. Perhaps
more alarming is the mounting data that these LSCs can actively induce changes
in the BM microenvironment not only at the structural level but in cytokine
production and genetic/epigenetic abnormalities within supporting BM stromal
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cells.33,34 Co-culture experiments have shown that HSCs cultured on BM stroma
collected from AML patients have a pronounced impairment in both self-renewal
and survival capacity, while LSCs lose neither attribute on AML or normal
stroma.
Thus LSCs induce changes to the BM microenvironment and supporting
cells which favor LSC survival and maintenance while simultaneously
compromising its ability to support and maintain normal HSC survival and
differentiation. These interactions add another layer of complexity, additional to
the dramatic heterogeneity of AML, which again must be accounted for in model
systems that will ultimately be useful in the development of successful
therapeutic paradigms that will truly translate to clinical care. Again in vivo animal
studies remain the only reliable way to examine the highly complex interplay
between leukemic populations (LSC and blast populations) and the protected BM
niche, and by extension the pharmacological efficacy of novel therapeutics.
Finally, in vivo methodologies have been shown to have significant advantages in
success rates of experimental drugs as compared to in vitro techniques which
often show success in the lab, but due to the lack of an accurate organ specific
extracellular environment, cross talk between hormone or different cell types,
differential metabolism, and site specific delivery often fail to show efficacy in
clinical trials. This remains especially true for AML as effective novel therapeutics
must be able to target the largely quiescent and protected LSC population
residing in the bone marrow, or alternatively target the bone marrow
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microenvironment to make it unfavorable for leukemic growth or promote normal
hematopoiesis.
The development of the first immune deficient strains of mice in the 1960s
overcame a major technical hurdle required to create such more clinically
relevant xenograft mouse models which allow for the engraftment of human cells.
Attempts are now even being made to replicate human cytokine signaling
through transgenic mice that expressing human cytokines, thus starting to model
the exquisitely complex role of cytokine signaling in leukemic and normal
hematopoiesis. These “humanized” models, in which human cells can engraft
and function have become revolutionary in the study of both normal and
malignant human hematopoiesis, and will play a crucial role in the development
of new therapeutics and treatment paradigms.
Highly immune deficient mice have become indispensable to the study of
both normal and malignant human hematopoiesis, as these mice do not reject
human xenografts and support the differentiation and continued growth of human
cells. Discovered in 1962, nude or athymic mice were the first immune
compromised mouse strain capable of accepting human cells and tissues and
soon after severe combined immune deficiency (SCID) mice.35 SCID mice
completely lack the ability to mount and sustain effective adaptive immune
responses, due to an absence of functioning T and B lymphocytes, caused by a
recessive mutation resulting in deficient activity of the enzyme; protein kinase,
DNA activated, catalytic polypeptide (Prkdc). This enzyme is crucial in DNA
damage repair as well as required for V(D)J recombination which explains how
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this mutation disrupts the maturation and function of T and B lymphocytes. SCID
mice were found to be far superior to nude mice in terms of engraftment of
human tissues, and further refinement came with the development of non-obese
diabetic (NOD)/SCID mice through the introduction of the Prdkcscid gene into an
inbreeding NOD strain.36,37 These mice showed even greater rates of human cell
engraftment as compared to SCID mice. Similarly, mice with that have a
defective recombination activated gene (RAG, can be either Rag1/2null) also
display a SCID phenotype and were crossed with NOD mice resulting in
NOD/Rag1/2null mice also capable of reliable human tissue growth and
engraftment.38,39 Numerous iterations of transgenic (NOD)/SCID mice capable of
expressing various human cytokines were developed in an attempt to further
improve rates of engraftment and promote true multilineage hematopoiesis,
growth, and differentiation of human hematopoetic cells.40
The early 2000s saw the advent of a series of immune deficient mice
appropriate for the creation of truly “humanized” mouse models that showed not
only high rates of engraftment, but also well-differentiated multilineage expansion
and engraftment of human leukemia or HSCs. These mice were developed
through the introduction of a mutant IL2ry gene into (NOD)/SCID mice through
respective backcross mating, resulting in the generation of the two most widely
used strains of immune deficient mice, NOG and NSG mice, which are
(NOD)/SCID IL-2rynull and differ only in the location of the SCID mutation.41,42
Inactivation of IL-2ry, which is shared by several cytokines (IL-2, IL-4, IL-7, IL-15
and IL-21) crucial to T- and B-cell growth, allowed for much better multilineage
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immune suppression and overcame the inherent “leakiness” observed in
NOD/SCID mice, which eventually develop T- and B-cells with age.43 This
mutation was also introduced into and (NOD)/Rag1/2null mice to generate NRG
[(NOD)/Rag1/2null IL-2rynull)] mice, whose immune impairment is dependent on
hematopoietic specific RAG deficiency, thus leaving DNA repair intact.
Functionally these mice were a revolutionary leap in xenograft mouse
models of human leukemia and show multiple immune deficiencies well beyond
lymphocytic impairment. These mice exhibit defects in T, B, and natural killer
(NK) cells as well as markedly reduced dendritic cell and macrophage function. 41
Extremely enhanced engraftment rates of human cell lines, HSCs, and even
primary patient samples have been observed, as well as well-defined
differentiation and maturation of multiple distinct hematopoietic lineages upon
human HSC xenograft as compared to parent strains. Of particular importance
was the finding that these mice support the differentiation and proliferation of
human T-cells, specifically CD4 and CD8 single positive cells, which do not
develop in NOD/SCID mice. Indeed these strains, particularly the NSG mouse,
have become the workhorses for modeling and studying human leukemogenesis
and hematopoiesis in an in vivo system that begins to attempt to mimic
physiological conditions experienced by leukemic cells in the human body. Such
in vivo systems that are capable of faithfully replicating physiological conditions,
and support the proliferation of human or patient derived leukemia, are critical in
the search for novel therapeutics that have a high potential of advancing to
clinical trials and/or becoming approved therapies.

16

While these mice provided a revolutionary leap in the study of both normal
and leukemic human hematopoiesis, they fail to model several important
conditions experienced by human AML patients. The most glaring and obvious
disadvantage is the lack of a fully functional immune system, especially the
lymphocytic compartment which is severely impaired to allow for the engraftment
and proliferation of human cells. Attempts are now being made to develop mice
with “humanized” immune systems, and essentially rely on transplantation of
normal human CD34+ HSCs into competent immune compromised mice. Several
groups have been able to show well characterized differentiation along multiple
well defined hematopoietic lineages, and most importantly the presence of
human T and B lymphocytes. Unfortunately the utility of these “humanized”
mouse systems remain insufficient as the resulting human cells are often times
not fully functional, and fail to produce immunomodulatory molecules like
cytokines and IgG upon antigen presentation.44 Mouse models of human
leukemia that can eventually incorporate a functional human immune system will
be required for truly translational investigation of novel therapeutics, especially
immune based therapies.
Second, and perhaps as important, is the lack of hematopoietic cytokine
signaling as most mouse cytokines do not cross react with human cells. This is a
major shortcoming as cytokine production and signaling is known to be required
for both normal human hematopoiesis and plays a role in leukemic progression
and clinical outcome. Additionally, this signaling is required for reliable homing,
engraftment, and proliferation of both normal human HSCs, and xenograft patient
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samples which are notoriously difficult to engraft.45 To overcome this problem
several groups have developed a series of NOG and NSG mice that express
transgenes for a variety of human cytokines specifically geared to the desired
area of research (e.g. hIL-2, hIL-3, hIL-6, hGM-CSF, etc.).41,46,47 This
development further improved these models by allowing for the engraftment,
differentiation, and development of patient derived leukemia or normal human
HSC in a BM microenvironment, as well as limited human cytokine signaling.
Despite these advances NOG and NSG mice have major flaw that is often
overlooked, and is a result of a mutation in the Prdkc gene used to generate the
SCID phenotype. This gene and its enzyme product Prdck are required for not
only V(D)J recombination of lymphocytes but also DNA damage repair. As such
these mice are highly intolerant to chemotherapeutics, especially DNA damaging
agents, as they are unable to repair any of the damage caused by the drugs.
This poses a significant challenge as the standard of care induction therapy for
AML uses doxorubicin (or other anthracyclines like daunorubicin or idarubicin)
and cytarabine, both DNA damaging compounds. Doxorubicin intercalates DNA
thereby preventing macromolecular biosynthesis and through stabilization of
topoisomerase II promotes breaks in the DNA. Cytarabine or cytosine
arabinoside interferes with DNA synthesis due to rapid conversion to a toxic and
DNA damaging intermediate, when the cell is in the S phase and replicating
DNA. Thus mice harboring SCID immune deficiencies are extremely intolerant to
treatment with these drugs, even at subtoxic doses in other mouse strains, a
critical flaw. Truly translational models must be able to closely mimic the patient
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experience, as well as model the standard of care therapy not only as a more
relevant control, but also to investigate innovative and/or combinatorial
therapeutics. Taken together a more clinically and translationally relevant mouse
model of AML will require not only mice capable of receiving and supporting
human patient xenografts, but also express human myeloid cytokines and
tolerate aggressive chemotherapeutic treatment similar to clinical induction
therapy.
Recently, Mulloy et. Al. developed a new strain of mice by crossing NRG
mice with NSGS mice which are essentially NSG mice that harbor the SGM3
(3GS) triple coinjected transgenes that express human interleukin 3 (IL-3),
granulocyte/macrophage colony stimulating factor (GM-CSF), and steel factor
(SF). Upon genotyping of the offspring, selective breeding together or with NRG
mice allowed for the removal of the SCID mutation resulting in NRGS mice which
are essentially NRG mice that also express the SGM3 transgene. Thus these
mice have no mature T cells, B cells, or NK cells due to the hematopoetic
specific Rag mutation (as opposed to a SCID mutation) and express three
human cytokines important for both engraftment and support of human myeloid
cells. Since these mice do not depend on a SCID mutation to mediate immune
suppression they have functional DNA repair and should be able to tolerate
clinically comparable doses of chemotherapeutics and previous studies have
shown that these mice maintain the radioresistance that is a hallmark of the NRG
strain. This strain of mice is truly cutting edge in terms of modeling human
hematopoiesis, both normal and malignant, as not only can these mice tolerate
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aggressive induction chemotherapy and dose escalation, but also express three
human cytokines necessary for the engraftment and support of human myeloid
cells.
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HYPOTHESIS
We hypothesize that we can develop a more clinically relevant xenograft
mouse model of human AML for the investigation of novel therapeutics and
treatment paradigms. This is essential, especially for AML which is a uniquely
heterogeneous cancer that presents with a variety of morphologies and express
a diverse array of genetic and molecular irregularities, each with their own
associated treatment sensitivities and clinical outcomes. Our model is hinged on
NRGS mice which will not only allow for high rates of human AML cell
engraftment, but will also attempt to recapitulate some human myeloid cytokine
signaling. Finally, the model must be resilient enough to tolerate aggressive
induction chemotherapy at doses similar to those experienced by AML patients,
and treatment with induction chemotherapeutics must provide a significant
survival outcome in mice engrafted with human AML. Establishment of such a
model will be crucial to the discovery of novel compounds, whose efficacy
against patient specific AML can be tested against and in combination with
standard of care induction therapy. Compounds identified in this model system
are expected to have considerably improved success rates in advancement to
clinical trials and hopefully improve patient treatment outcomes and remission
rates.
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MATERIALS AND METHODS
ANIMAL STUDIES
NRGS mice were obtained from Jackson laboratories and bred and maintained at
the University of Louisville Rodent Research Facility (RRF) on a 12-hour light/12hour dark cycle and provided food and water ad libitum. Animals were maintained
under standard conditions and all animal procedures were approved by the
Institutional Animal Care and Use Committee. In all studies the appropriate number
of human AML cells from established lines, patient derived cells, or MYC/BCLXL
induced murine leukemia were resuspended in PBS and tail vein injected at a final
volume of 200 µl. Mice receiving “5+3” therapy were weighed daily and given a dose
of 75 mg/kg of cytarabine for five days and 3 mg/kg doxorubicin for three days by
bolus tail vein injection, with each injection being balanced with PBS such that each
mouse receives a total volume of 200 µl. Mice in the vehicle groups received
injections of 200 µl plain PBS for all five days. Upon development of leukemia or
termination of the experiment mice were sacrificed and FACS analysis conducted on
the spleen, thymus, and BM
REAGENTS AND ANTIBODIES
Clinical formulations of both doxorubicin and cytarabine were obtained from the
James Graham Brown Cancer Center as single dose self-sealing vials containing 20
mg/10 ml or 2g/20ml respectively, manufactured by APP a division of Fresenius Kabi
USA LLC (Lake Zurich, IL).
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CELL CULTURE
Cells were maintained in culture at 37° C under 5% CO2 in RPMI 1460 growth media
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.
PATIENT SAMPLES
Patient derived AML cells obtained from the spleen of an NSG mouse engrafted with
the primary patient leukemia, were a generous gift from our collaborator Dr. James
Mulloy, at Cincinnati Children’s Hospital.
FACS ANALYSIS
Both the spleen and BM were analyzed by FACS. In brief, single cells were isolated
from tissues; red blood cells were lysed and blocked for 10 mins at room
temperature with Fc Block (#553142 BD Biosciences, Miami, FL, USA). The
samples were then stained with anti-human CD45 antibody conjugated to the Alexa
700 fluorophore, from BioLegend (San Diego, CA) for 20 mins at 4° C and then
analyzed on a Becton Dickinson FACScan with FlowJo.
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RESULTS
Engraftment of multiple human AML cell lines in NRGS mice. First we wanted to
examine the engraftment and subsequent disease progression of NRGS mice tailvein injected with 1 x 105 human AML cells. Differential rates of engraftment based
on leukemic subtype and classification were examined by injecting either OCI-AML3
cells or KG1 cells. Each of these cell lines represent dramatically different subtypes
of AML and therefore the utility of this model for multiple cytogenetically distinct
subtypes of AML encountered in the clinical setting. Three NRGS mice were injected
with 1 x 105 of each cell line and monitored until humane endpoints were achieved.
We found that both cell lines showed high rates of consistent engraftment (n=3) as
quantified by the amount of detectable human CD45 in the spleen and BM by FACS.
Mice injected with OCI-AML3 cells survived till approximately 30 days till human
endpoints were reached, while mice injected with KG1 cells survived only 23-25
days. This data corresponds to these cell lines in vitro growth rate as well as their
subtype associated aggressiveness. These data indicated that NRGS mice are
capable of high rates of engraftment and fairly rapid disease progression when
injected with established human cell lines, allowing for the establishment of model
systems that are capable of investigating novel therapeutics against various human
AML subtypes in an in vivo environment with the influence of human myeloid
cytokines.
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Figure 1. Engraftment of 1 x 105 OCI-AML3 cells in NRGS mice. NRGS mice
(n=3) were injected with 1 x 105 OCI-AML3 cells and maintained under standard
conditions until humane endpoints were reached as characterized by distress,
breathing difficulty, hind limb paralysis, etc. Mice had to be sacrificed from 30-32
days after injection of cells and FACS analysis of the BM and spleen showed a large
percentage of human cells (representative mouse shown). Approximately 30% of the
cells in the spleen (A.) were human OCI-AML3 cells and surprisingly almost 50% of
the BM. (B.) was comprised of human cells. The left column represents unstained
cells, to ensure that results were irrespective of inherent cellular auto-florescence.
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Figure 2. Engraftment of 1 x 105 KG1 cells in NRGS mice. NRGS mice (n=3)
were injected with 1 x 105 KG1 cells and maintained under standard conditions until
humane endpoints were reached as characterized by distress, breathing difficulty,
hind limb paralysis, etc. Mice had to be sacrificed after 23-25 days after injection of
cells and FACS analysis of the BM and spleen showed a large percentage of human
cells (representative mouse shown). Only 18% of the cells in the spleen were human
KG1 cells and again almost 50% of the BM was comprised of human cells. Again the
left hand column indicates analysis of unstained cells to account for any possible
inherent auto fluorescence of the cells.
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Engraftment of patient derived AML cells in NRGS mice. Once we were able to
establish that high rates of engraftment and predictable disease progression could
be achieved in our model using established human cells lines, we wanted to
progress to the engraftment of notoriously difficult human patient derived AML cells.
Previous studies have demonstrated that similar immune deficient mouse models of
human AML can accurately predict patient chemotherapeutic response, and faithfully
maintain the unique genetic and phenotypic identity of engrafted patient AML. We
also wanted to confirm similar findings in our model, these findings being a
prerequisite to a truly physiologically, translationally, and clinically relevant mouse
model of AML. Therefore, the cells were examined by FACS analysis for human
myeloid markers both pre-injection and post sacrifice. Thus, NRGS mice (n=5) were
tail-vein injected with 1.25 x 105 patient derived AML cells (as determined by FACS
analysis for human CD45) and maintained under standard conditions until visible
signs of leukemia were evident and humane endpoints achieved. All mice had to be
terminated at 41 days after injection of cells, and most mice showed overt signs of
leukemia, like hind limb paralysis. FACS analysis of both the BM and the spleen
showed the presence of a large percentage of human cells with the same myeloid
antigen expression as compared to cells pre-injection, indicating that engraftment of
the patient sample was successful. Interestingly both CD14 and CD33 are virtually
undetectable upon defrost, but are heavily expressed after transplantation into the in
vivo environment. These data indicate that NRGS mice are valuable tools that allow
for the robust engraftment of both human cell lines, and more importantly primary
patient derived AML cells.
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Figure 3. FACS analysis of human myeloid cell surface markers upon defrost
and before tail vein injection into NRGS recipients. After thawing the cells FACS
analysis was conducted using antibodies against human CD45, CD33, CD11b, and
CD14. Since these cells were acquired from the spleens of NSG mice transplanted
with the primary patient leukemia approximately 41.7% of the cells were of human
origin as characterized by human CD45 expression. The cells were positive only for
huCD45 and huCD11b and showed no expression of huCD33, a common myeloid
cell surface antigen, or huCD14 an antigen expressed by a variety of mature
hematopoietic lineages.
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Figure 4. FACS analysis of human myeloid cell surface markers after injection
and sacrifice of NRGS mice injected with 1.25 x 105 patient derived AML cells.
After humane endpoints were achieved at 41 days, the mice were sacrificed and
their hematopoetic organs were examined by FACS analysis to determine the
percentage of human cells as well as examine the maintenance of cell surface
marker expression. As expected there were a high percentage of human cells as
identified by CD45 expression, and these cells maintained their human myeloid cell
surface expression as compared to the patient cells upon defrost, with the exception
of CD33 and CD14 which were detectable.
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Treatment of leukemia in mice with a clinically similar dosing regimen of
induction chemotherapeutics. As discussed in detail previously the current
standard of care therapy for AML centers around administration of an anthracycline
(doxorubicin, daunorubicin, idarubicn etc.) for three days combined with continuous
infusion of cytarabine (Ara-C) for seven days and therefore often called “7+3”. Based
on published studies from a collaborator, Dr. James Mulloy, we utilized his “5+3”
regimen for mice which has been scaled down taking into account both body mass
as well as differences in pharmacokinetics, but done using a different stain of mice.
Therefore it was of crucial importance for us to investigate the efficacy of our
treatment regimen in mice harboring leukemia, to be used as both a more relevant
control and for investigation of combinatorial therapies. Thus, NRGS mice
transplanted with patient AML cells were allowed to incubate for a week at which
time they began daily tail vein injections of 75 mg/kg cytarabine for five days, and
doxorubicin at 3 mg/kg for the first three days. Recognizing a major criticism of
these mouse models, including the lack of a functional immune compartment and
the feasibility issues associated with the acquisition of primary patient samples, we
also decided to test the efficacy of this same chemotherapeutic regimen on wild-type
FVB mice engrafted with our own in house transplantable murine myeloid leukemia.
This leukemia was generated by retroviral induced overexpression of Myc and
BCLXL in normal BM hematopetic progenitors as previously described. This would
provide an easier and more high-throughput methodology for screening novel
therapeutics against and in combination with standard of care therapies, along with
the influence of a fully functional immune compartment. Additionally, Myc is
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recognized as one of the most potent oncogenes and BCLXL an extremely potent
proliferative signal making this myeloid leukemia extremely aggressive. Therapies
showing efficacy in this model will therefore have a high likelihood of success in
clinical trials against patient leukemias which are generally much less aggressive.
Here we show for the first time that “5+3” therapy with doxorubicin and cytarabine
results in a significant enhancement of survival in both NRGS mice engrafted with
patient derived AML cells and in FVB mice receiving our MYC/BCLxL induced
murine myeloid leukemia. The survival benefit was much more pronounced in the
NRGS mice with patient derived leukemia resulting in an average increase in
survival of 12 days as compared to the vehicle treated mice. FVB mice engrafted
with MYC/BCLxL induced myeloid leukemia show a diminished but still significant
response to “5+3” induction therapy, with survival being prolonged by an average of
7 days. Both these results indicate that NRGS mice are capable of handling
aggressive chemotherapeutic treatment with standard of care therapy in a manner
similar to the clinical experience of patients. Perhaps more importantly these data
indicate that our treatment regimen is actually capable of treating both mice
engrafted with patient derived leukemia and murine leukemia, a crucial finding,
especially if this regimen is used as a control for efficacy and for studies of
combinatorial therapy.

31

Figure 5. Treatment of NRGS mice engrafted with patient derived AML using
“5+3” induction therapy. NRGS mice (n=10) were tail vein injected with 1.25 x 105
patient derived AML cells obtained from the spleen of an NSG mouse engrafted with
the primary patient leukemia and maintained under standard conditions for seven
days. Next one group (n=5) was given “5+3” induction therapy composed of 3 mg/kg
doxorubicin for the first three days and 75 mg/kg cytarabine all five days, while the
vehicle group received sham injections of the vehicle PBS. Survival was significantly
prolonged by an average of 12 days indicating that our clinically modeled regimen is
effective in the treatment of patient derived leukemia, a crux in the development of a
more clinically relevant AML mouse model that better recapitulates patient
experience, and also as a control during the investigation of novel therapeutics.
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Figure 6. Treatment of MYC/BCLXL induced murine myeloid leukemia in wild
type FVB recipients with functional immune systems. FVB mice (n=10) were tailvein injected with 5 x 105 spleenocytes taken from an FVB mouse after development
of MYC/BCLXL induced leukemia and sacrifice, and maintained under standard
conditions for seven days. One group of mice (n=5) received “5+3” induction therapy
with 75 mg/kg cytarabine administered all five days and 3 mg/kg doxorubicin for the
first three days, while the vehicle group (n=5) received sham injections of PBS.
Chemotherapeutic treatment significantly increased survival by an average of 7
days, indicating that our dosing regimen is also effective against an extremely
aggressive murine myeloid leukemia, albeit with decreased efficacy as compared to
treatment of patient leukemia. Most importantly this model has a fully functional
immune system allowing for more physiologically accurate investigation of
therapeutics, especially immune therapies.
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Humanization of NRGS mice. The absolute pinnacle in the development of
xenograft mouse models of patient AML would be the influence of a functional
human immune system in addition to patient specific leukemia. Therefore we
attempted to engraft sub-lethally irradiated NRGS mice (n=3) with human CD34+
multipotent HSCs obtained from umbilical cord blood, in the hope that we could
observed multi-lineage expansion of human cells in the mouse microenvironment.
Approximately 100 days after injection these mice were sacrificed and their spleens
and BM analyzed by FACS analysis for the presence of several linage restricted
human cell surface markers. Two of the three mice in this arm of the study showed
the presence of human cells in the bone marrow, while all three mice showed no
detectable human cells in the spleen. The mature human myeloid marker CD33
could be detected at low levels in the BM (3.54%, 9.34%), and the human Blymphocyte antigen CD19 could be detected at higher levels (8.67%, 27.6%). Mouse
#2 even stained positive for the human T-cell receptor CD3 at a detectable level
(0.6%). These results demonstrate that NRGS mice are capable of being humanized
upon sub-lethal irradiation and tail-vein injection of human CD34+ multipotent HSCs.
The eventual goal of these studies is to incorporate a functional human immune
system into our more clinically relevant patient xenograft AML mouse model, and
these data demonstrate feasibility.
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Figure 7: FACS analysis of BM from sub-lethally irradiated NRGS mice
engrafted with 5 x 105 human CD34+ HSCs. All three mice were sacrificed
approximately 100 days post-injection of cells and their spleens and BM stained for
the presence of huCD33, huCD19, and huCD3. Only the BM of two of the three mice
stained positively and showed detectable expression of the three surface antigens.
Mouse #1 showed 3.54% huCD33+, 8.67% huCD19+, and 0.059% huCD3+ cells in
the bone marrow, while Mouse #2 had considerably higher engraftment with 9.34%
huCD33+, 27.6% huCD19+, and 0.6% huCD3+ cells.
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DISCUSSION
As previously emphasized acute myeloid leukemia displays a vast
heterogeneity that is exquisitely unique to individual patients, and each case
presents widely varied prognoses and drug sensitivities. Therefore investigation of
novel therapeutic compounds and treatment strategies for AML that have a high
likelihood of success in clinical trials require the development of truly translational
mouse models, capable of recapitulating patient specific disease as well as standard
of care therapy. Previous studies over the past 50 years have led to the
development of immune deficient mouse models that are capable of supporting the
growth and proliferation of both established human AML cell lines as well as primary
patient samples, and these models have become widespread in the study of AML.
However, several major hurdles remain in the development of a truly clinically
relevant mouse models of AML namely the lack of human cytokine signaling, lack of
a functional immune system, poor engraftment rates of primary patient samples, and
finally the inability to tolerate clinically relevant doses of standard of care
chemotherapy. Thus the focus of this study was to establish mouse models of AML
pathogenesis that could overcome these issues, and more sound methodology for
the investigation of novel therapeutics in a patient specific manner.
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Our studies hinged on a newly developed strain of mice dubbed NRGS, which
expresses three human cytokines and have functional DNA repair, and first we
investigated the engraftment of established human AML cell lines (representing
distinct subtypes) and subsequent leukemogenisis. Mice were tail vein injected with
1x 106 OCI-AML3 or KG1 cells and similar to observed in vitro growth rates mice
engrafted with OCI-AML3 cells developed leukemia and had to be sacrificed in 3032 days, while mice injected with KG1 cells had to sacrificed in only 23-25 days. All
mice showed distinct signs of leukemic distress including hind limb paralysis as well
as breathing difficulties, and necropsy revealed pronounced splenomegaly in all
mice. This correlates with growth rates obseverved in vitro with KG1 cells showing a
much faster growth rate and doubling time as compared to OCI-AML3 cells. Analysis
of the spleen and BM showed the presence of human cells in both locations with
approximately 50% of the cells in the BM identified as human cells, through human
CD45 expression, upon injection of both cell lines. Interestingly OCI-AML3 cells
were found at a much higher percentage in the spleen (approximately 30%) as
compared to KG1 cells possibly indicating differential preference of location based
on AML subtype. Finally both FACS analysis of surface markers and visual
morphology of human cells isolated from the BM and/or the spleen confirmed the
faithful maintenance of the human phenotype in the mouse microenvironment.
These data indicate that NRGS mice allow for the reliable engraftment of human
AML cells of varied subtype, and eventually develop fatal human leukemia
detectable in the spleen and bone marrow.

37

After confirming reliable rates of engraftment and consistent leukemic
progression using established human cell lines we examined the engraftment of
patient derived leukemia, obtained from the spleen of an NSG mouse after tail vein
injection of primary patient AML and subsequent sacrifice upon development of
leukemia. 1.25 x 105 patient AML cells were injected into NRGS mice and 41 days
later a humane endpoint was achieved and all mice had to be sacrificed with most
displaying either hind limb paralysis or breathing difficulties. This data indicates that
NRGS mice show reliable rates of efficient sample engraftment as well as
predictable disease progression, both essential to our model system. FACS analysis
of human cells obtained upon sacrifice showed continued expression of CD45 and
CD11b as compared to initial analysis of the cells upon thawing. However after
exposure to the in vivo environment and possibly the human cytokines, patient cells
harvested from leukemic NRGS mice showed a strong expression of both CD33 as
well as CD14, both undetectable upon defrost or short term in vitro cell culture.
These findings highlight the importance of not only the in vivo microenvironment, but
also human cytokine signaling, and suggest that they are crucial to accurately
maintain the patient specific AML phenotype. In future studies it will be critical to
examine the engraftment of primary patient samples taken directly from the clinic as
our cells were passaged once through an NSG mouse which may have resulted in
selection for cells that were best adapted to the mouse microenvironment. The
expression of human cytokines (IL-3, GM-CSF, and SF) is expected to greatly
facilitate the implantation and engraftment of primary patient cells, but this remains
to be investigated in our hands.
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Perhaps the most important goal of this study was to establish a clinically
comparable and efficacious dosing regimen of induction therapy using doxorubicin
and cytarabine. Based on the work of our collaborator Dr. Jim Mulloy, we tested a
“5+3” induction therapy regimen composed of bolus tail vein injections of 3 mg/kg
doxorubicin for the first three days and 75 mg/kg cytarabine for five days, which was
shown to be well tolerated in NRG mice and comparable to clinically experienced
doses of these drugs.48 Therapy using this dosing regimen was highly efficacious in
the treatment of NRGS mice engrafted with our patient derived leukemia and
resulted in a significant increase in average survival of 11.4 days. These data are
crucial to our model system as we conclusively show that not only can NRGS mice
be reliably engrafted with patient derived AML cells and develop leukemia, but also
that our “5+3” induction therapy regimen is effective in treating patient derived
leukemia and provides a significant survival advantage. Future studies will not only
attempt to escalate the dose of induction therapeutics but also use this regimen as a
more relevant control during the study of novel therapeutics, alone and/or as
combinatorial therapy, against patient derived AML.
A major shortcoming not addressed by this model is the influence of a
functional immunity on both leukemic progression and therapeutic efficacy of
experimental therapeutics. In an attempt to test our “5+3” induction therapy regimen
in a model with a functional immune system we injected 5 x 105 spleenocytes from a
WT FVB mouse harboring our own in house murine AML, into sub-lethally irradiated
WT FVB recipient mice and after a week these mice were put on our “5+3” regimen.
This AML is generated by simultaneous retroviral overexpression of MYC and
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BCLxL in normal WT FVB BM hematopoetic progenitors. MYC is widely recognized
as one of the most potent oncogenes and BCLxL an extremely strong proliferative
signal, and overexpression of both in hematopoetic progenitors result in an
extremely aggressive and transplantable murine AML. Data obtained from this study
clearly indicates that our model induction therapy regimen also provides a significant
survival advantage to WT FVB mice transplanted with aggressive MYC/BClxL
induced AML, and a fully functional immune system.
Additionally, we attempted to engraft sub-lethally irradiated NRGS mice with
normal human CD34+ HSCs to determine if multilineage expansion of human
immune cells was possible. While human cells of both the T- and B-lineage were
detected in two of the three mice in the study, the rates of differentiation and
expansion were generally poor. While disappointing, these results highlight the
feasibility of developing NRGS mice with normal functional human immunity in
conjunction with patient derived AML. It is likely that conditioning of the mice is
required for the engraftment of human HSCs and their subsequent differentiation
and expansion into immune cells.
Novel therapeutics and combinatorial therapies, especially immune based
therapies, could be tested for efficacy alone and in combination with the standard of
care therapy in such a model, and compounds that show efficacy in both models will
most likely have a higher likelihood of success in clinical trials. The successful
discovery of truly translational novel therapeutics for AML will hinge on the
development and implementation of similar, more clinically relevant mouse models
of patient specific AML that faithfully recapitulate the unique cytogenetic and
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morphological profile of patient disease, the influence of the BM microenvironment,
human cytokine signaling, and finally the influence of a functional immune
compartment.
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